PRESS RELEASE

NERVIANO MEDICAL SCIENCES

Nerviano Medical Sciences Srl Announces its plan to focus its portfolio on three biological targets and ADC platform

NERVIANO, Italy, 23 July 2025 — Nerviano Medical Sciences Srl (NMS Srl or NMS), a clinical stage biopharmaceutical leader in oncology innovation, announced its strategic plan to focus its research and development resources to progress its three biological targets, composed of PARP1, PARP7, and MPS1, and on its proprietary ADC platform composed of novel ADC payloads.

Itareparib (PARP1 Inhibitor)
A next-generation, highly selective PARP1 inhibitor engineered to avoid PARP trapping, a key source of toxicity in healthy cells. Its differentiated profile enables safe and effective combination with DNA-damaging agents like chemotherapy and ADCs. Currently in **Phase II** for **relapsed glioblastoma (IDH wild type)** in combination with temozolomide, itareparib has shown strong bone marrow tolerability[1] supporting its expansion into **astrocytoma**, **small cell lung cancer**, and **non-BRCA ovarian cancer**.

Atamparib (PARP7 Inhibitor)
A potent, oral PARP7 inhibitor targeting tumors driven by mono-ADP ribosylation activity. With high selectivity and a strong safety profile in early trials, atamparib offers a novel approach in oncology where PARP7 plays a critical role in disease progression. Positioned for **Phase II entry in 2025**, it addresses significant unmet needs in targeted patient populations.

NMS-153 (MPS1/TTK Inhibitor)
A selective mitotic kinase inhibitor designed to disrupt cancer cell division and trigger immune-activating cell death. Currently in **Phase I/II** for **hepatocellular carcinoma in combination with Atezolizumab**, MPS1 has shown confirmed responses in monotherapy[2] and combination activity in preclinical models, offering a versatile mechanism for tumors resistant to standard therapies.

ADC Platform
A next-generation ADC platform centered on proprietary novel payload-linker technologies designed to overcome drug resistance. The platform offers a compelling balance of potency and safety, with modular design enabling seamless integration with external antibody assets. NMS's ADC platform can support the expansion of NMS's own internal ADC pipeline and a growing network of external collaborations.

[1] Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor. Guerts M et al. Mol Cancer Ther 1 December 2023; 22 (12_Supplement): LB_A12.
[2] NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma, Reig, M. et al., European Journal of Cancer, 2022, Volume 174, S2.

While NMS's three biological targets exhibit compelling differentiation based on strong preclinical validation and favorable emerging clinical data, its ADC platform also has potential for strong growth based on advanced next-generation payloads.

In order to focus its research and development resources on the above activities, NMS Srl has informed its unions and employees of its intention to wind down laboratory operations at the BioN campus in Nerviano, Italy. NMS Srl will also relocate its office-based operational headquarters to Corsico (Milan), Italy.

"This is a pivotal moment for NMS," said Hugues Dolgos, Pharm.D., CEO of NMS. *"By streamlining operations and strategically focusing our research and development resources efforts on our most promising biological targets and clinical assets, we are taking decisive steps to drive our long-term success based on our unique successful history and capabilities."*

NMS expects the transition to be implemented immediately after the conclusion of the information and consultation procedure with labor unions. NMS's clinical programs and business development activities will continue and will not be affected during or after the information and consultation procedure.

About Nerviano Medical Sciences

Nerviano Medical Sciences S.r.l. focuses on discovering and clinically developing small molecule NCEs for oncology, aiming to deliver first- and best-in-class personalized cancer treatments through innovative mechanisms and novel drug targets. Our pipeline, built from our validated kinase platform, includes projects from early preclinical to clinical stages, advanced both internally and in partnership.

NMS Srl combines biotech agility with big pharma quality, guided by an experienced management team and a skilled staff with global expertise in research, drug discovery, and clinical development. A core strength lies in our renowned kinase inhibitor platform, featuring an extensive chemical library and IP coverage, which has led to successful out-licensing deals, including encorafenib and entrectinib. Additionally, we are advancing a PARP-family-focused platform to discover NCEs targeting NAD-binding pockets, with potential expansion to other NAD-dependent enzymes. Our growing payload-linker platform further enhances our pipeline by enabling next-generation ADC production.

Collaborating globally with academic, clinical, and industry partners, we seek further strategic alliances to develop, commercialize, and expand our product portfolio while exploring in-licensing opportunities for promising clinical assets

For more information, visit https://www.nervianoms.com.

Media Relations: mediarelations@nervianoms.com